Elevated CXCL16 levels within the tumor niche also promote the conversion of stromal cells into cancer-associated fibroblasts (CAFs) in both preclinical models and patient samples of ARID1A-deficient EC. The gene discussed is CXCL16; the disease is neoplasm.